Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

THOUSAND OAKS and SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that nearly 40 company-sponsored and investigator-sponsored investigational studies evaluating carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in early development, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA.

"We are encouraged by the breadth of data from our Proteasome Inhibitor franchise being presented this year at ASH, which add to the clinical data of carfilzomib in combination with other therapies and provide further insight into the level of response for carfilzomib at a molecular level. Additionally, data to be presented on oprozomib offer clinical insights instrumental in driving forward our clinical development program for the compound," said Pablo Cagnoni, M.D., President of Onyx Pharmaceuticals, Inc.  "We remain committed to bringing innovative therapies to patients in need, and we look forward to playing a continued role in advancing the scientific understanding of hematologic malignancies."

Among the presentations are five abstracts from the Proteasome Research and Integrative Science for Multiple Myeloma – Novel Therapies Program (PRISM NTP), a global research collaboration between Onyx, investigators at myeloma centers of excellence and partner companies with novel therapies in development. "The PRISM program further demonstrates our commitment to innovation and advancing science," said Homa Yeganegi, Vice President of Scientific Affairs a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... TOKYO, Oct. 22 /Xinhua-PRNewswire/ -- Olympus Capital Holdings ... reached an agreement to,sell Arysta LifeScience Corporation, the ... for an enterprise value of,approximately JPY 250 billion ... for Olympus Capital, a leading middle market private,equity ...
... 21 Boston,Scientific Corporation (NYSE: BSX ) ... patients from its TAXUS ARRIVE 1 and 2 ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The ... events and repeat,revascularization through two years in complex ...
... be Webcast as Part of AACR Virtual Meeting -, ... RGDX ) today announced that Kathleen Danenberg, the ... on the role,of pharmacogenomics in tailoring medicine at the ... will be held October 22-26, 2007 at the Moscone ...
Cached Biology Technology:Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
(Date:4/23/2014)... Aires yesterday, Argentina joins the European Molecular Biology ... move strengthens the ties between the European and ... scientists access to EMBL,s world-class facilities and programs, ... its inception, fostering excellent life science research and ... of EMBL,s mission," says EMBL Director General Iain ...
(Date:4/23/2014)... cli-fi, is a newly coined term for novels and films ... from University of Copenhagen shows how these fictions serve as ... consequences of climate change and imagine other living conditions. ... changes in the atmosphere; it is also a cultural phenomenon ... read and the films we see. And there are so ...
(Date:4/23/2014)... most comprehensive study to date of the family ... more effective vaccine strategies and reveals surprising findings ... results could alter public health strategies to control ... each year. , Genomic analysis of 343 strains ... around the world collected over the last 100 ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Impact of whooping cough vaccination revealed 2
... AGA Research Foundation and Horizon Pharma further establish their ... the 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the ... third year, this competition continues to grow in popularity ... in basic and clinical research," said Nicholas F. LaRusso, ...
... declining worldwide and a major cause is a deadly fungus ... shows they can also die from this pathogen, contrary to ... spreads the disease. When researchers raised the frogs from ... strain of this pathogen, Batrachochytrium dendrobatidis , also called ...
... news release is available in French . ... in older mice with Alzheimer,s disease can be reversed with treatment. ... - The Neuro, at McGill University and at Universit de Montral ... brain of mice with advanced Alzheimer,s disease (AD) recovers memory and ...
Cached Biology News:Horizon Pharma Abstract Prizes recognize promising fellows and students 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... RNase ONE Ribonuclease is a 27kDa periplasmic ... degradation of RNA to cyclic nucleotide monophosphate ... degradation of these intermediates to 3-NMPs (1). ... few known RNases that can cleave a ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... is designed for paramagnetic bead precipitation from ... PCR plates with no additional accessories. The ... a standard SBS 96-well microplate footprint. The ... guarantees easy and fast (as little as ...
Biology Products: